Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and...
Clinical Trial
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention...
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the...
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while...
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec....
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved...
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume...
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and...
Apollomics Reports First Half 2025 Financial Results
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Trump’s Marijuana Schedule III Order Launches a Federally Regulated Healthcare Sector
MMJ's position is further fortified by its FDA Orphan Drug Designations for the treatment of Huntington's Disease. These designations are...
Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness
Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations LAGUNA HILLS,...
Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness
Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations LAGUNA HILLS,...
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist,...
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative...
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest...
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva...
CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors
HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some...
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA...